McKesson: Drug Recall
Recall #D-0213-2025 · 01/17/2025
Class II: Risk
Recall Details
- Recall Number
- D-0213-2025
- Classification
- Class II
- Product Type
- Drug
- Recalling Firm
- McKesson
- Status
- Ongoing
- Date Initiated
- 01/17/2025
- Location
- Irving, TX, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 192 vials
Reason for Recall
cGMP Deviations: Product intended for quarantine was inadvertently distributed.
Product Description
Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01
Distribution Pattern
Nationwide USA
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.